Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eaton Vance Ohio Municipal Income Trust (NQ: EVO )

3.640 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eaton Vance Ohio Municipal Income Trust

< Previous 1 2 3 4 5 6 7 Next >
Evotec and X-Chem Collaborate to Accelerate Early-Stage Drug Discovery
From X-Chem
Via Business Wire
Evotec Announces Change in Management Board
Via ACCESSWIRE
Hain Celestial Posts Upbeat Q4 Earnings, Joins Soleno Therapeutics, Energizer Holdings And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Bristol Myers' German Partner Evotec Plans Layoffs, Cites 'Challenging Revenues, Profitability'
Evotec reports a rise in Q2 sales to $201.12M but posts an EPS loss of $0.54. CEO Christian Wojczewski cites market challenges and outlines cost-cutting measures, including a 7% workforce reduction. 
Via Benzinga
Topics Workforce
Exposures Layoff
Evotec Announces Strong Progress in Strategic Protein Degradation Partnership with Bristol Myers Squibb
Via ACCESSWIRE
Evotec Announces Progress in Strategic Neuroscience Partnership with Bristol Myers Squibb
Via ACCESSWIRE
Evotec SE Provides Guidance Update
Via ACCESSWIRE
EVO Stock Earnings: Evotec Misses EPS, Misses Revenue for Q2 2024
EVO stock results show that Evotec missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
Evotec SE Reports H1 2024 Results: Challenging Year; Priority Reset for Sustainable Profitable Growth Gaining Momentum, Building on Core Strengths
Via ACCESSWIRE
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Pre-market stock movers are a hot topic on Wednesday and we have all of the latest news traders need to know about them this morning! 
Via InvestorPlace
Why Fortinet Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Evotec Provides Guidance Update
Via ACCESSWIRE
Evotec and Pfizer Collaborate to Advance Drug Discovery in France
Via ACCESSWIRE
Just - Evotec Biologics Expands Tech Partnership for Biosimilars with Sandoz
Via ACCESSWIRE
Evotec SE Reports First Half-year 2024 Results on 14 August 2024
Via ACCESSWIRE
Delta Air Lines Posts Downbeat Earnings, Joins United Airlines, American Airlines And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
Just - Evotec Biologics selected by U.S. Department of Defense for Manufacturing Optimization Program
Via ACCESSWIRE
German Drug Developer Evotec Seeks Adviser Input As Takeover Concerns Mount
Evotec consults defense advisers following a significant share price decline, raising concerns about a potential takeover. 
Via Benzinga
Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Why Nurix Therapeutics Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Via Benzinga
AMC Networks, Louisiana-Pacific And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Evotec Announces Progress in Neuroscience Collaboration with Bristol Myers Squibb
Via ACCESSWIRE
Evotec SE: Results of the Annual General Meeting 2024
Via ACCESSWIRE
Evotec Reports Q1 2024 Results and Provides Corporate Update
Via ACCESSWIRE
Evotec, Inserm, Lille University Hospital and Inserm Transfert Enter Collaboration to Identify Novel Therapeutic Targets in Obesity and Metabolic Diseases
Via ACCESSWIRE
Evotec and CHDI Foundation Extend Strategic Drug Discovery Collaboration in Huntington’s Disease
Via ACCESSWIRE
EVO Stock Earnings: Evotec Beats EPS, Beats Revenue for Q1 2024
EVO stock results show that Evotec beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Evotec SE to Announce Results for First Quarter 2024 on 22 May 2024
Via ACCESSWIRE
CENTOGENE and Evotec Discover Promising New Molecule to Treat Gaucher Disease
From Centogene NV
Via GlobeNewswire
3 Growth Stocks to Buy at 52-Week Lows
Looking for some compelling bargains? It's time to add these three growth stocks at 52-week lows to your watchlist. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.